TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice

Oral Diseases

Volumn 18, Issue 4, 2012, Pages 365-374

  Vosters, J L ^a,b   Roescher, N ^a,b   Illei, G G ^b   Chiorini, J A ^b   Tak, P P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Gene therapy; Non obese diabetic mice; Salivary gland; Sj gren's syndrome; TACI Fc

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PARVOVIRUS VECTOR; SYNDECAN 1; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND FUNCTION; SALIVATION; SIALOADENITIS; SJOEGREN SYNDROME; VIRAL GENE THERAPY;

ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CYTOKINES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLAMMATION MEDIATORS; LIGANDS; MICE; MICE, INBRED NOD; PLASMA CELLS; RECOMBINANT FUSION PROTEINS; SALIVA; SECRETORY RATE; SIALADENITIS; SJOGREN'S SYNDROME; SUBMANDIBULAR GLAND; SYNDECAN-1; TRANSDUCTION, GENETIC; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84859100106     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01885.x     Document Type: Article

References (56)

1. Badr G, Borhis G, Lefevre EA et al (2008). BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 111: 2744-2754.
2. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB (2001). Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 60: 660-669.
3. Castigli E, Scott S, Dedeoglu F et al (2004). Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 101: 3903-3908.
4. Charles P, Elliott MJ, Davis D et al (1999). Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163: 1521-1528.
5. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P (2009). Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun 33: 190-196.
6. Fox RI (2005). Sjogren's syndrome. Lancet 366: 321-331.
7. Gatto B (2008). Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 9: 1216-1227.
8. Groom J, Kalled SL, Cutler AH et al (2002). Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109: 59-68.
9. Gross JA, Johnston J, Mudri S et al (2000). TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999.
10. Gross JA, Dillon SR, Mudri S et al (2001). TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 15: 289-302.
11. Hahne M, Kataoka T, Schroter M et al (1998). APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188: 1185-1190.
12. Hansen A, Odendahl M, Reiter K et al (2002). Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 46: 2160-2171.
13. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP (2005). Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 7: R862-R867.
14. Huard B, Schneider P, Mauri D, Tschopp J, French LE (2001). T cell costimulation by the TNF ligand BAFF. J Immunol 167: 6225-6231.
15. Huard B, McKee T, Bosshard C et al (2008). APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 118: 2887-2895.
16. Jonsson R, Gordon TP, Konttinen YT (2003). Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjogren's syndrome. Curr Rheumatol Rep 5: 311-316.
17. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K (2005). Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 25: 189-201.
18. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K (2006). Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum 54: 2300-2305.
19. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA (2001). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75: 6884-6893.
20. Khoury M, Adriaansen J, Vervoordeldonk MJ et al (2007). Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med 9: 596-604.
21. Liu W, Szalai A, Zhao L et al (2004). Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 50: 1884-1896.
22. Lombardi T, Moll S, Youinou P et al (2011). Absence of up-regulation for a proliferation-inducing ligand in Sjogren's sialadenitis lesions. Rheumatology (Oxford) 50: 1211-1215.
23. Mackay F, Woodcock SA, Lawton P et al (1999). Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 1697-1710.
24. Mackay F, Sierro F, Grey ST, Gordon TP (2005). The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 8: 243-265.
25. Mariette X, Ravaud P, Steinfeld S et al (2004). Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 50: 1270-1276.
26. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A (2000). Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10: 785-788.
27. Meijer JM, Meiners PM, Vissink A et al (2010). Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 960-968.
28. Moore PA, Belvedere O, Orr A et al (1999). BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
29. Morel J, Roubille C, Planelles L et al (2009). Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 68: 997-1002.
30. Pena-Rossi C, Nasonov E, Stanislav M et al (2009). An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18: 547-555.
31. Pers JO, Daridon C, Devauchelle V et al (2005). BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050: 34-39.
32. Planelles L, Carvalho-Pinto CE, Hardenberg G et al (2004). APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6: 399-408.
33. Ramanujam M, Wang X, Huang W et al (2004). Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 173: 3524-3534.
34. Ramanujam M, Wang X, Huang W et al (2006). Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116: 724-734.
35. Richardson SM, Wheelan SJ, Yarrington RM, Boeke JD (2006). GeneDesign: rapid, automated design of multikilobase synthetic genes. Genome Res 16: 550-556.
36. Roescher N, Tak PP, Illei GG (2010). Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis 69: 945-948.
37. Roescher N, Lodde BM, Vosters JL et al (2011). Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjogren's syndrome. Oral Dis. doi: 10.1111/j.1601-0825.2011.01852.x. [Epub ahead of print].
38. Salomonsson S, Jonsson MV, Skarstein K et al (2003). Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 48: 3187-3201.
39. Salomonsson S, Rozell BL, Heimburger M, Wahren-Herlenius M (2009). Minor salivary gland immunohistology in the diagnosis of primary Sjogren's syndrome. J Oral Pathol Med 38: 282-288.
40. Sankar V, Brennan MT, Kok MR et al (2004). Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50: 2240-2245.
41. Skarstein K, Wahren M, Zaura E, Hattori M, Jonsson R (1995). Characterization of T cell receptor repertoire and anti-Ro/SSA autoantibodies in relation to sialadenitis of NOD mice. Autoimmunity 22: 9-16.
42. Stein JV, Lopez-Fraga M, Elustondo FA et al (2002). APRIL modulates B and T cell immunity. J Clin Invest 109: 1587-1598.
43. Stohl W, Metyas S, Tan SM et al (2004). Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 63: 1096-1103.
44. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R (1995). Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155: 5038-5045.
45. Szodoray P, Jonsson R (2005). The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 62: 421-428.
46. Tak PP, Thurlings RM, Rossier C et al (2008). Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58: 61-72.
47. van der Hall PO, Kraan MC, Tak PP (2007). Quantitative image analysis of synovial tissue. Methods Mol Med 135: 121-143.
48. Van Mello NM, Pillemer SR, Tak PP, Sankar V (2005). B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjogren's syndrome. Ann Rheum Dis 64: 471-473.
49. Vosters JL, Landek-Salgado MA, Yin H et al (2009a). Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjogren's syndrome. Arthritis Rheum 60: 3633-3641.
50. Vosters JL, Yin H, Roescher N, Kok MR, Tak PP, Chiorini JA (2009b). Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjogren's syndrome. Arthritis Res Ther 11: R189.
51. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999). Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 42: 1765-1772.
52. Voutetakis A, Kok MR, Zheng C et al (2004). Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. Proc Natl Acad Sci USA 101: 3053-3058.
53. Wang H, Marsters SA, Baker T et al (2001). TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2: 632-637.
54. Wu AJ, Chen ZJ, Tsokos M, O'Connell BC, Ambudkar IS, Baum BJ (1996). Interferon-gamma induced cell death in a cultured human salivary gland cell line. J Cell Physiol 167: 297-304.
55. Wu Y, Bressette D, Carrell JA et al (2000). Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 275: 35478-35485.
56. Xia XZ, Treanor J, Senaldi G et al (2000). TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 192: 137-143.